GH Replacement Improves Quality of Life and Metabolic Parameters in Cured Acromegalic Patients with Growth Hormone Deficiency
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Objective Effects of GH replacement in patients with GH deficiency (GHD) after a cure for acromegaly so far have been poorly studied, although its prevalence among acromegalic patients may reach the 60%. The aim of the study was to evaluate whether metabolic parameters and quality of life are improved by GH replacement in patients with prior acromegaly and severe GHD. Design and methods This was a prospective study on 42 GHD subjects [22 men, mean age (sd): 48 ± 10]: 10 acromegalics treated with recombinant human GH (group A), 12 acromegalics who refused treatment (group B), and 20 subjects operated for nonfunctioning pituitary adenoma on recombinant human GH (group C). Serum IGF-I levels, lipid profile, glucose levels (fasting and after an oral glucose tolerance test), glycosylated hemoglobin, insulin resistance (homeostasis model assessment insulin resistance index), anthropometric parameters (body mass index, waist circumference, body composition), and quality of life (Questions on Life Satisfaction-Hypopituitarism Z-scores) were evaluated at baseline and after 12 and 36 months. Results At baseline, group B showed higher IGF sd score than group A and C, as well as better quality of life and higher post-oral glucose tolerance test glucose levels than group A. After 12-months, similarly in group A and C, the IGF-I sd score significantly increased, and body composition and lipid profile improved, without deterioration of glucose tolerance. Quality of life significantly improv…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Rates of pituitary axes recovery or new onset hypopituitarism after transsphenoidal surgery vary significantly between studies (115,233,234).”
From Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline (2016) · cites this paper as [234]
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423 · cited 1×
“The low-density lipoprotein (LDL)-cholesterol levels were calculated by the following formula: LDL-cholesterol [(total cholesterol HDL) TG/5] (21).”
MethodMatthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502 · cited 1×
“Insulin resistance was determined using the homeostasis model assessment (20): homeostasis model assessment insulin resistance index fasting insulin (milliunits per liter) fasting glucose (milligrams per deciliter)/22.”
MethodSalomon, F., Cuneo, R. C., Hesp, R., & Sönksen, P. H. (1989) · New England Journal of Medicine · doi:10.1056/nejm198912283212605 · Cited by 1,326
Molitch, M. E., Clemmons, D. R., Malozowski, S., Merriam, G. R., & Vance, M. L. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0179 · Cited by 1,047
A Consensus on Criteria for Cure of Acromegaly
Giustina, A., Chanson, P., Bronstein, M. D., Klibanski, A., Lamberts, S., Casanueva, F. F., Trainer, P., Ghigo, E., Ho, K., & Melmed, S. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2670 · Cited by 783 · cited 1×
“Acromegalics were considered cured according to the current guidelines (14).”
BackgroundClinical Aspects of Growth Hormone Deficiency in Adults
BOER, H. D., BLOK, G.-J., & DER VEEN, E. A. V. (1995) · Endocrine Reviews · doi:10.1210/edrv-16-1-63 · Cited by 723
Clinical aspects of growth hormone deficiency in adults
de Boer, H. (1995) · Endocrine Reviews · doi:10.1210/er.16.1.63 · Cited by 402
Corneli, G., Di Somma, C., Baldelli, R., Rovere, S., Gasco, V., Croce, C. G., Grottoli, S., Maccario, M., Colao, A., Lombardi, G., et al. (2005) · European Journal of Endocrinology · doi:10.1530/eje.1.01967 · Cited by 317
Optimizing Growth Hormone Replacement Therapy by Dose Titration in Hypopituitary Adults
Drake, W. M., Coyte, D., Camacho‐Hübner, C., Jivanji, N. M., Kaltsas, G., Wood, D., Trainer, P. J., Grossman, A. B., Besser, G. M., & Monson, J. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.83.11.3913 · Cited by 236
Predictors of morbidity and mortality in acromegaly: an Italian survey
Arosio, M., Reimondo, G., Malchiodi, E., Berchialla, P., Borraccino, A., De Marinis, L., Pivonello, R., Grottoli, S., Losa, M., Cannavò, S., et al. (2012) · European Journal of Endocrinology · doi:10.1530/eje-12-0084 · Cited by 219
Self-citationPorretti, S., Giavoli, C., Ronchi, C. L., Lombardi, G., Zaccaria, M., Valle, D., Arosio, M., & Beck‐Peccoz, P. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.5.2042 · Cited by 112 · cited 1×
“Moreover, because it is known that rhGH therapy may unmask or worsen a central hypothyroid or hypoadrenal state (18, 19), in groups A and C, both hypothalamic-pituitary-thyroid and hypothalamic-pituitary-adrenal axes were reevaluated no later than 6 months after the start of rhGH, and the other replacement therapy was…”
BackgroundSelf-citationGiavoli, C., Libé, R., Corbetta, S., Ferrante, E., Lania, A., Arosio, M., Spada, A., & Beck-Peccoz, P. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1114 · Cited by 97 · cited 1×
“Moreover, because it is known that rhGH therapy may unmask or worsen a central hypothyroid or hypoadrenal state (18, 19), in groups A and C, both hypothalamic-pituitary-thyroid and hypothalamic-pituitary-adrenal axes were reevaluated no later than 6 months after the start of rhGH, and the other replacement therapy was…”
BackgroundSelf-citationFeldt-Rasmussen, U., Abs, R., Bengtsson, B., Bennmarker, H., Bramnert, M., Hernberg-Stahl, E., Monson, J., Westberg, B., Wilton, P., & Wuster, C. (2002) · European Journal of Endocrinology · doi:10.1530/eje.0.1460067 · Cited by 84
Blum, W. F., Shavrikova, E. P., Edwards, D. J., Rosilio, M., Hartman, M. L., Marín, F., Valle, D., van der Lely, A. J., Attanasio, A. F., Strasburger, C. J., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021792 · Cited by 78 · cited 1×
“Quality of life was assessed with validated Questions on Life Satisfaction-Hypopituitarism (QLS-H) self-administered questionnaire (22).”
MethodMiller, K. K., Wexler, T., Fazeli, P., Gunnell, L., Graham, G. J., Beauregard, C., Hemphill, L., Nachtigall, L., Loeffler, J., Swearingen, B., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1611 · Cited by 66
Jayasena, C. N., Comninos, A. N., Clarke, H., Donaldson, M., Meeran, K. M., & Dhillo, W. S. (2011) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.04019.x · Cited by 54 · cited 1×
“Acromegaly is a disabling disease caused by chronic GH and IGF-I hypersecretion, mostly due to a pituitary tumor, and associated with increased cardiovascular morbidity and mortality (1, 2).”
Backgroundvan der Klaauw, A. A., Bax, J. J., Roelfsema, F., Stokkel, M. P. M., Bleeker, G. B., Biermasz, N. R., Smit, J. W. A., Romijn, J. A., & Pereira, A. M. (2009) · Pituitary · doi:10.1007/s11102-009-0186-y · Cited by 41 · cited 3×
“J Clin Endocrinol Metab, November 2012, 97(11):3983–3988 jcem.”
BackgroundInfluentialLin, E., Wexler, T. L., Nachtigall, L., Tritos, N., Swearingen, B., Hemphill, L., Loeffler, J., Biller, B. M. K., Klibanski, A., & Miller, K. K. (2012) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2012.04361.x · Cited by 37 · cited 1×
“As recently published, GHD has detrimental effects on body composition and biomarkers of cardiovascular risk in patients with previous acromegaly, too (8).”
BackgroundNorrman, L.-L., Johannsson, G., Sunnerhagen, K. S., & Svensson, J. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2673 · Cited by 37 · cited 2×
“Even though GHD in previously acromegalic patients is the same syndrome affecting adults with GHD from other etiologies (9, 10), rhGH replacement experience in these patients is still limited, few reports have been so far published, and longterm data are lacking.”
BackgroundResultPrevalence of GH deficiency in cured acromegalic patients: impact of different previous treatments
Ronchi, C. L., Giavoli, C., Ferrante, E., Verrua, E., Bergamaschi, S., Ferrari, D. I., Corbetta, S., Montefusco, L., Arosio, M., Ambrosi, B., et al. (2009) · European Journal of Endocrinology · doi:10.1530/eje-09-0222 · Cited by 34 · cited 1×
“In a previous paper, we demonstrated in a group of 56 cured acromegalic subjects that the prevalence of GHD reached the 60%, independently from previous type of treatment, being the same in patients treated with surgery alone or with surgery followed by radiotherapy (3).”
ResultSelf-citationvan der Klaauw, A. A., Pereira, A. M., van Thiel, S. W., Smit, J. W. A., Corssmit, E. P. M., Biermasz, N. R., Frolich, M., Iranmanesh, A., Veldhuis, J. D., Roelfsema, F., et al. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02163 · Cited by 24 · cited 1×
“This test has been previously validated in the acromegalic population (16, 17).”
Valassi, E., Brick, D. J., Johnson, J. C., Biller, B. M. K., Klibanski, A., & Miller, K. K. (2012) · Endocrine Practice · doi:10.4158/ep11134.or · Cited by 19 · cited 2×
“As far as quality of life, our results are supported by a recent study reporting an improvement after 6 months of rhGH in women with GHD and a previous history of acromegaly, improvement that was even greater than that observed in women with GHD due to other hypothalamic-pituitary disorders (13).”
ResultEvaluation of growth hormone stimulation tests in cured acromegalic patients
Conceição, F. L., Fisker, S., Andersen, M., Kaal, A., Jørgensen, J. O. L., Vaisman, M., & Christiansen, J. S. (2003) · Growth Hormone & IGF Research · doi:10.1016/s1096-6374(03)00124-2 · Cited by 14 · cited 1×
“This test has been previously validated in the acromegalic population (16, 17).”
Cited by
Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline
Fleseriu, M., Hashim, I. A., Karavitaki, N., Melmed, S., Murad, M. H., Salvatori, R., & Samuels, M. H. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2118 · Cited by 945
Systemic Complications of Acromegaly and the Impact of the Current Treatment Landscape: An Update
Gadelha, M. R., Kasuki, L., Lim, D. S. T., & Fleseriu, M. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00115 · Cited by 363
Andela, C. D., Scharloo, M., Pereira, A. M., Kaptein, A. A., & Biermasz, N. R. (2015) · Pituitary · doi:10.1007/s11102-015-0636-7 · Cited by 142
Diabetes in Patients With Acromegaly
Hannon, A. M., Thompson, C. J., & Sherlock, M. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0838-7 · Cited by 111
Primary Empty Sella Syndrome and the Prevalence of Hormonal Dysregulation
Auer, M. K., Stieg, M. R., Crispin, A., Sievers, C., Stalla, G. K., & Kopczak, A. (2018) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2018.0099 · Cited by 99
“On the other hand, treating hormonal dysregulation has a positive effect on morbidity and quality of life (3, 4).”
Background
Metadata
- Authors
- Giavoli, C., Profka, E., Verrua, E., Ronchi, C. L., Ferrante, E., Bergamaschi, S., Sala, E., Malchiodi, E., Lania, A. G., Arosio, M., Ambrosi, B., Spada, A., & Beck-Peccoz, P.
- Affiliations
- University of Milan (IT)
- Universitätsklinikum Würzburg (DE)
- Department of Clinical Sciences and Community Health (C.G., E.P., E.V., E.F., S.B., E.S., E.M., M.A., A.S., P.B.-P.), University of Milan,
- Corresponding author
- Giavoli, Claudia
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2012-11-01
- Volume
- 97
- Issue
- 11
- Pages
- 3983-3988
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2103849796
- Semantic Scholar
- f46ac07a1ce3daaaae24563b2d5c4d4f20a30af6
- Cited by
- 25
- References
- 22
- Citations by year
- 2024: 1 · 2023: 1 · 2022: 2 · 2018: 4 · 2017: 4 · 2016: 2 · 2015: 3 · 2014: 7
- FWCI
- 2.56
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Reproductive Medicine › Hypothalamic control of reproductive hormones
- Keywords
- growth hormone replacement therapy, acromegaly, growth hormone deficiency, recombinant human growth hormone, quality of life, insulin-like growth factor I, lipid profile, glucose tolerance, insulin resistance, body composition, hypopituitarism, non-functioning pituitary adenoma
- MeSH terms
- Acromegaly, Adult, Blood Glucose, Female, Humans, Insulin-Like Growth Factor I, Lipids, Male, Middle Aged, Prospective Studies, Quality of Life, Recombinant Proteins, Treatment Outcome, Human Growth Hormone, Hormone Replacement Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.